# Assessment of KAN-101 in Celiac Disease (ACeD)

> **NCT04248855** · PHASE1 · COMPLETED · sponsor: **Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA** · enrollment: 41 (actual)

## Conditions studied

- Celiac Disease

## Interventions

- **DRUG:** KAN-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04248855
- **Lead sponsor:** Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-21
- **Primary completion:** 2021-10-08
- **Final completion:** 2021-10-08
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2024-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04248855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04248855, "Assessment of KAN-101 in Celiac Disease (ACeD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04248855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*